Page last updated: 2024-11-06

procainamide hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Procainamide hydrochloride is an antiarrhythmic drug used to treat atrial fibrillation and ventricular tachycardia. It is a sodium channel blocker that prolongs the action potential duration in the heart, which helps to prevent the rapid and irregular heartbeats that characterize these arrhythmias. Procainamide hydrochloride is typically administered intravenously or orally. It is synthesized by reacting procaine with hydrochloric acid. Procainamide hydrochloride has been studied extensively for its effects on the cardiovascular system. It is important to note that procainamide hydrochloride can have serious side effects, including lupus-like syndrome and agranulocytosis. Therefore, it is important to use procainamide hydrochloride only under the supervision of a physician.'

procainamide hydrochloride : A hydrochloride which has procainamide as the amino component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66068
CHEMBL ID605
CHEBI ID8429
SCHEMBL ID40758
MeSH IDM0017608

Synonyms (129)

Synonym
AC-7552
MLS001148635
benzamide, 4-amino-n-[2-(diethylamino)ethyl]-, monohydrochloride
AKOS008056264
pronestyl hydrochloride
MLS000069436 ,
smr000059079
EU-0100995
benzamide, 4-amino-n-(2-(diethylamino)ethyl)-, monohydrochloride
benzamide, p-amino-n-(2-(diethylamino)ethyl)-, hydrochloride
ccris 7143
procan sr
procanbid
4-aminobenzoesaeure-2-diethylaminoethylester hydrochlorid
supicane amide hydrochloride
procainamide hcl
einecs 210-381-7
procainhydrochlorid
pronestyl-sr
promide hydrochloride
procan-sr hydrochloride
procamide hydrochloride
procapan hydrochloride
p-amino-n-(2-(diethylamino)ethyl)benzamide hydrochloride
procainii chloridum
procardyl hydrochloride
procaine amide hydrochloride
4-amino-n-(2-(diethylamino)ethyl)benzamide monohydrochloride
novocamid hydrochloride
p-amino-n-(2-(diethylamino)ethyl)benzamide monohydrochloride
procapan
procainamide hydrochloride
BIM-0050968.0001
procanbid (tn)
D00477
614-39-1
procainamide hydrochloride (jp17/usp)
pronestyl (tn)
procan sr (tn)
NCGC00094291-03
NCGC00094291-02
SPECTRUM1500503
NCGC00094291-01
NCGC00094291-05
NCGC00094291-04
hydrochloride, procainamide
4-amino-n-[2-(diethylamino)ethyl]benzamide hydrochloride
CHEBI:8429 ,
P 9391
VU0239777-5
4-amino-n-(2-diethylaminoethyl)benzamide hydrochloride
nsc-757279
CHEMBL605
amidoprocaine
procainamidi hydrochloridum
cardiorytmin
HMS1569C15
HMS1920L04
unii-si4064o0lx
benzamide, 4-amino-n-(2-(diethylamino)ethyl)-, hydrochloride (1:1)
si4064o0lx ,
procainamide hydrochloride [usp:jan]
nsc 757279
dtxsid2049422 ,
tox21_202855
dtxcid1029382
NCGC00260401-01
pharmakon1600-01500503
nsc757279
S4294
CCG-39233
FT-0603493
LP00995
EPITOPE ID:140114
procainamide hydrochloride [who-dd]
procainamide hydrochloride [ep monograph]
4-amino-n-(2-(diethylamino)ethyl)benzamide monohydrochloride [who-ip]
p-amino-n-(2-(diethylamino)ethy)benzamide monohydrochloride
procainamide hydrochloride [who-ip]
procainamide hydrochloride [mart.]
procainamide hydrochloride [usp monograph]
procainamide hydrochloride [usp-rs]
procainamide hydrochloride [orange book]
procainamidi hydrochloridum [who-ip latin]
procainamide hydrochloride [vandf]
procainamide hydrochloride [jan]
procainamide hydrochloride [mi]
NC00535
SCHEMBL40758
KS-5258
4-amino-n-(2-diethylamino-ethyl)-benzamide hcl
ABTXGJFUQRCPNH-UHFFFAOYSA-N
NCGC00261680-01
tox21_500995
7699-39-0
4-amino-n-[2-(diethylamino)ethyl]benzamide;hydrochloride
W-105155
procainamidehydrochloride
HY-A0084
procainamide (hydrochloride)
OPERA_ID_1543
4-amino-n-[2-(diethylamino)ethyl]-benzamide hydrochloride
mfcd00012998
F0850-6742
procainamide hydrochloride, purum, >=98.0% (at)
sr-01000000022
SR-01000000022-2
procainamide hydrochloride, united states pharmacopeia (usp) reference standard
4-amino-n-(2-(diethylamino)ethyl)benzamide hydrochloride
procainamide hydrochloride, european pharmacopoeia (ep) reference standard
procainamide hydrochloride, pharmaceutical secondary standard; certified reference material
SR-01000000022-6
procainamide hydrochloride, >=98% (hplc)
SW196878-3
Q27108080
BCP28404
AMY22225
A14240
EN300-20309
D97622
4-amino-n-[2'-(diethylamino)ethyl]benzamide hydrochloride
Z104477706
procainamide hydrochloride (usp:jan)
procainamide hydrochloride (ep monograph)
4-amino-n-(2-diethylaminoethyl)benzamide monohydrochloride
procainamide hci
procainamide hydrochloride (mart.)
procainamide hydrochloride (usp monograph)
procainamide hydrochloride (usp-rs)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency14.12540.044717.8581100.0000AID485294
acetylcholinesteraseHomo sapiens (human)Potency63.62230.002541.796015,848.9004AID1347398
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
GLI family zinc finger 3Homo sapiens (human)Potency65.08220.000714.592883.7951AID1259392
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency34.55110.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.36900.000229.305416,493.5996AID743075
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.05010.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.933023.934123.934123.9341AID1967
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency3.16233.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency22.38720.01789.637444.6684AID588834
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency100.00000.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency0.00400.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID218734In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as % change for the functional refractory period (FRP) at 10 uM at concentration range of 0.1-100 uM1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID1133695Antiarrhythmic activity in aconitine-induced mongrel dog arrhythmic model assessed as atrial rate measured at end of infusion at 48 +/- 38 mg/kg, iv1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID218603In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as maximum % change for conduction time(CT) at 0.1-100 uM concentration range; Minimal (<10% decrease or increase inCT).1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID60247Percent of normal beats 1 hr after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1133725Antiarrhythmic activity in ip dosed ICR mouse assessed as protection against chloroform-induced ventricular fibrillation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1133698Antiarrhythmic activity in aconitine-induced mongrel dog arrhythmic model assessed as decrease in ventricular rate rate measured at end of infusion at 48 +/- 38 mg/kg, iv (Rvb = 205 +/- 65 BPM)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID218747In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as maximum % change for functional refractory period (FRP) at 0.1-100 uM concentration range; concentration at which it occurred is 100 uM.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID220658In vitro electrophysiological activity in canine cardiac occurred is 1 uM.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID1133716Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as 50% repolarization time at 20 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 223 +/- 11 ms)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID151312Antiarrhythmic activity estimated by using the ouabain intoxicated dog model and the active dose of base in ouabain dog was reported.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1133723Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as spontaneous intrinsic rate at 10 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 33 +/- 5 BPM)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID220934In vitro electrophysiological evaluation in canine cardiac occurred is 100 uM.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID220655In vitro electrophysiological activity in canine cardiac occurred is 100 uM.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID220799In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as % change for action potential duration at 10 uM at 1-100 uM concentration range1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID1133720Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as 90% repolarization time at 20 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 284 +/- 12 ms)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID218587In vitro electrophysiological evaluation in canine cardiac ventricular muscle reported as % change for conduction time(CT) at 0.1-100 uM concentration range; Minimal (<10% decrease or increase inCT).1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID1133704Antiarrhythmic activity in aconitine-induced mongrel dog arrhythmic model assessed as atrial rate at 48 +/- 38 mg/kg, iv after 17 +/- 16 mins from end of infusion1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1133728Therapeutic index, ratio of LD50 for ICR mouse assessed as acute mortality to ED50 for protection against chloroform-induced ventricular fibrillation in ICR mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID60248Percent of normal beats 20 min after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1133701Antiarrhythmic activity in aconitine-induced mongrel dog arrhythmic model assessed as mean arterial blood pressure measured at end of infusion at 48 +/- 38 mg/kg, iv (Rvb = 70 +/- 8 mmHg)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1133692Plasma concentration in mongrel dog at 48 +/- 38 mg/kg, iv1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID220802In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as % change for action potential duration at a concentration of 10 uM1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID76705Parasympatholytic activity and the % inhibition of guinea pig ileum contractile force at 4 mg/L of base was reported.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3).
AID1133711Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as rate of phase 0 depolarization (dV/dt) at 10 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 491 +/- 40 V/s)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1133719Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as 90% repolarization time at 10 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 274 +/- 30 ms)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID60249Percent of normal beats after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1133727Toxicity in ip dosed ICR mouse assessed as acute mortality1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID57671Activity rating following 100.5 mg/kg i.v. administration.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1133724Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as spontaneous intrinsic rate at 20 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 35 +/- 7 BPM)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1133707Antiarrhythmic activity in aconitine-induced mongrel dog arrhythmic model assessed as decrease in ventricular rate rate at 48 +/- 38 mg/kg, iv after 17 +/- 16 mins from end of infusion (Rvb = 205 +/- 65 BPM)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1133712Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as rate of phase 0 depolarization (dV/dt) at 20 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 474 +/- 57 V/s)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID220950In vitro electrophysiological evaluation in canine cardiac Purkinje fibres reported as percent change Vmax at 10 uM at concentration range of 1-100 uM; Minimal (<10% decrease or increase in Vmax).1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and cardiac electrophysiological activity of 2- and 3-[(substituted phenyl)alkyl]quinuclidines. Structure-activity relationships.
AID1133715Antiarrhythmic activity in mongrel dog Purkinje fiber assessed as 50% repolarization time at 10 ug/ml by Single Cell Potentials/electrophysiological technique (Rvb = 244 +/- 15 ms)1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl) benzamide (the p-hydroxy isostere of procainamide) in dogs and mice.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (17.65)18.7374
1990's1 (5.88)18.2507
2000's2 (11.76)29.6817
2010's9 (52.94)24.3611
2020's2 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.99 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index72.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]